Publications by authors named "Subhashis Banerjee"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

22,779

Total Likes

549

Extended Reach

1,286,261

Social Features

27
S
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
Cyrielle Billon, Sadichha Sitaula, Subhashis Banerjee, Ryan Welch, Bahaa Elgendy, Lamees Hegazy, Tae Gyu Oh, Melissa Kazantzis, Arindam Chatterjee, John Chrivia

ACS Chem Biol· April 2023

Videos about Article: user user user

3 2 24 9 101

View All Article and Social Media Activity
E
Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.
Atul Deodhar, Miroslawa Nowak, June Y Ye, Tom Lehman, Subhashis Banerjee

Rheumatol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.
Jianzhong Zhang, Yangfeng Ding, Ping Wang, Linfeng Li, Weili Pan, Subhashis Banerjee

J Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabidiol improves learning and memory deficits and alleviates anxiety in 12-month-old SAMP8 mice.
Monica N Goodland, Subhashis Banerjee, Michael L Niehoff, Benjamin J Young, Heather Macarthur

PLoS One· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.
April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Akimichi Morita, Subhashis Banerjee

J Eur Acad Dermatol Venereol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.
Marta Mosca, Laurent Arnaud, Anca Askanase, Coburn Hobar, Brandon Becker, Subhashis Banerjee

Lupus Sci Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.
Arthur Kavanaugh, Laura C Coates, Philip J Mease, Miroslawa Nowak, Lauren Hippeli, Subhashis Banerjee

Rheumatology (Oxford)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.
Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Yukari Okubo, Katsuyoshi Habiro, Subhashis Banerjee

J Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study.
Kathryn Connelly, Rachel Koelmeyer, Darshini Ayton, John May, Kate Gregory, Subhashis Banerjee

Lupus Sci Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, Tan P Pham, Stacie Hudgens, Subhashis Banerjee

Dermatol Ther (Heidelb)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simulation training in mammography with AI-generated images: a multireader study.
Krithika Rangarajan, Veeramakali Vignesh Manivannan, Harpinder Singh, Amit Gupta, Hrithik Maheshwari, Subhashis Banerjee

Eur Radiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.
Jianzhong Zhang, Yangfeng Ding, Ping Wang, Linfeng Li, Weili Pan, Subhashis Banerjee

Br J Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study.
Yayoi Tada, April W Armstrong, Shinichi Imafuku, Yukari Okubo, Akimichi Morita, Subhashis Banerjee

J Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku, Subhashis Banerjee

JAMA Dermatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
Neil J Korman, Richard B Warren, Jerry Bagel, April W Armstrong, Melinda Gooderham, Subhashis Banerjee

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical, Biomarker, and Behavioral Characterization of the Grn Mouse Model of Frontotemporal Dementia.
Denise M Smith, Geetika Aggarwal, Michael L Niehoff, Spencer A Jones, Subhashis Banerjee

Mol Neurobiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.
Ian M Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, James G Krueger

Dermatol Ther (Heidelb)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.
Oliver FitzGerald, Dafna D Gladman, Philip J Mease, Christopher Ritchlin, Josef S Smolen, Subhashis Banerjee

Arthritis Rheumatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Bruce Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Subhashis Banerjee

J Eur Acad Dermatol Venereol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, Tan P Pham, Stacie Hudgens, Subhashis Banerjee

Dermatol Ther (Heidelb)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility and Explainability of Deep Learning in Mammography: A Systematic Review of Literature.
Deeksha Bhalla, Krithika Rangarajan, Tany Chandra, Subhashis Banerjee, Chetan Arora

Indian J Radiol Imaging· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Eric F Morand, Marilyn Pike, J Merrill, Ronald F van Vollenhoven, Victoria P Werth, Subhashis Banerjee

Expert Opin Investig Drugs· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F Merola, Subhashis Banerjee

J Am Acad Dermatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Subhashis Banerjee

Br J Dermatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Streamlining neuroradiology workflow with AI for improved cerebrovascular structure monitoring.
Subhashis Banerjee, Fredrik Nysjö, Dimitrios Toumpanakis, Ashis Kumar Dhara, Johan Wikström

Sci Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Shinichi Imafuku, Yukari Okubo, Yayoi Tada, Mamitaro Ohtsuki, Elizabeth Colston, Subhashis Banerjee

J Dermatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis